人工神经导管市场－全球产业规模、份额、趋势、机会与预测：材料、神经、电活性、应用、最终用途、地区和竞争格局，2021-2031年

全球人工神经导管市场预计将从 2025 年的 28.5 亿美元成长到 2031 年的 41.6 亿美元，复合年增长率为 6.51%。

这些由生物来源材料或合成聚合物製成的生物工程管状植入，透过桥接断裂的周边神经缺损并引导神经轴突再生发挥作用。市场成长的主要驱动因素是全球范围内因车祸和职业危害导致的创伤性损伤发生率不断上升，这迫切需要一个有效的神经修復方案。此外，老年人口的增长（老年人易患退化性神经病变）以及自体神经移植的局限性（例如供体部位併发症风险和组织短缺）进一步促使外科医生采用这些现成的再生替代方案。

先进导管系统的高成本和严格的报销政策给市场扩张带来了巨大挑战，限制了注重成本地区的患者获得此类治疗的机会。为了佐证创伤对市场需求的影响，美国国家安全委员会发布了2025年的初步数据，显示2024年美国约有44,680人死于车祸。这项统计数据反映了高速交通事故持续带来的沉重负担，而这类事故往往会导致复杂的神经损伤，需要手术修復。

市场驱动因素

3D列印和生物可吸收导管技术的进步正在从根本上重塑市场格局，克服了传统自体移植的局限性，例如组织来源有限和供体部位併发症。积层製造技术的创新使得製造具有精确微结构的导管成为可能，这些导管能够模拟天然细胞外基质，促进轴突导向和神经残端间的再生。这些现代支架经过精心设计，可完全生物吸收，无需二次手术取出，并能减少长期发炎反应。例如，2025年8月发表在PubMed Central上的一项研究表明，在小鼠模型中，3D列印的水凝胶导管实现了与标准自体移植相当的功能性运动神经再生，这表明这些合成材料可能成为一种可行的标准治疗方法。

创伤性週边神经损伤的发生率不断上升，这主要是由高衝击力机动车事故、职场危险因素和复杂手术等医源性损伤造成的，也是推动该领域发展的主要因素。日益加重的负担使得人们迫切需要可靠的、现成的修復方案来弥补神经缺损，尤其是在无法进行无张力修復的情况下。 2025年12月，ResearchGate的一项调查报告显示，手术全期週边神经损伤的发生率为每10万例手术住院患者中有14.6例，凸显了对有效再生医学介入措施的巨大需求。这种临床需求正在推动行业领先企业的财务成长。 2025年2月，Axogen公布了2024财年全年营收为1.873亿美元，年增17.8%，这主要得益于其先进神经修復技术的日益普及。

市场挑战

全球市场成长受到先进导管系统高成本和严格的报销政策的显着阻碍。预算紧张的医疗系统往往优先考虑成本控制，因此，当有更便宜的替代方案（例如直接缝合或自体移植）时，他们往往不愿意采用昂贵的生物工程植入。在一些地区，保险系统将这些器械归类为「研究性」或「选择性」器械，导致覆盖范围有限，从而加剧了这种财务压力。最终，医院和病患被迫承担这些费用，使得只有一小部分人能够获得这些器械。

这种经济差距严重限制了现成神经修復方案的广泛商业性应用。根据美国整形外科医师协会2024年的数据，神经导管修復手术的总费用中位数约为25,717美元，远高于标准的第一期修復技术。如此高昂的手术费用阻碍了其大规模应用，实际上将市场限制在资金雄厚的医疗机构，并阻止了该行业在全球范围内取代传统的、成本更低的治疗方法。

市场趋势

市场正从被动神经桥接转向主动生物修復，后者将神经营养因子融入导管设计中。製造商正优先研发能够生物刺激轴突再生的装置，以克服惰性导管在断裂损伤中的功能限制。随着支付方认识到功能恢復比简单的结构修復更具长期价值，这种向生物活性解决方案的转变正获得商业性支持。为了反映这一趋势，Axogen于2025年10月宣布，其神经修復产品线的保险覆盖范围已扩大至2025年约1810万名患者，这表明市场对先进再生演算法的需求日益增长。

同时，天然-合成混合复合材料的出现，结合了聚合物的机械耐久性和生物基质的生物相容性，正在优化植入的有效性。与容易引起发炎的第一代合成材料或缺乏刚性的纯生物材料不同，新一代复合材料，例如水凝胶增强细胞外基质，能够提供平衡的微环境，既支持细胞黏附，又能防止细胞崩坏。这项技术革新正在提升领先创新企业的财务表现。 2025年10月，Axogen公司宣布第三季营收达6,010万美元，年增23.5%，主要得益于该公司先进的混合生物系统。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球人工神经导管市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依材料分类（合成材料、生物来源、混合材料）
  • 依神经类型（接触引导、通道引导、微地形引导）
  • 依电活性（电活性、非电活性）分类
  • 依应用领域（週边神经修復、脊髓损伤修復、颅神经修復）
  • 依最终用途（医院、诊所、研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美人工神经导管市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲神经导管人工血管市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区人工神经导管市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲人工神经导管市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲人工神经导管市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球人工神经导管市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Axogen Corporation
• Axonics, Inc.
• Cytograft Tissue Engineering
• FibroGen, Inc.
• Eton Bioscience Inc.
• Kerimedical SA
• Synaptive Medical Inc.
• Stryker Corporation
• Newrotex Ltd
• Integra LifeSciences Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Artificial Nerve Conduits Market is projected to expand from USD 2.85 Billion in 2025 to USD 4.16 Billion by 2031, registering a CAGR of 6.51%. These bioengineered tubular implants, crafted from biological materials or synthetic polymers, are designed to bridge defects in severed peripheral nerves by guiding axonal regeneration across gaps. Market growth is primarily fueled by the increasing global incidence of traumatic injuries from vehicular accidents and occupational hazards, which demand effective nerve restoration solutions. Additionally, the growing geriatric population, which is prone to degenerative neuropathies, along with the limitations of autologous nerve grafts-such as donor site morbidity and tissue scarcity-further encourages surgeons to utilize these off-the-shelf regenerative alternatives.

High costs associated with advanced conduit systems and restrictive reimbursement policies pose a significant challenge to market expansion, limiting patient access in cost-conscious regions. Underscoring the impact of trauma on market demand, the National Safety Council reported preliminary data in 2025 indicating that approximately 44,680 motor vehicle fatalities occurred in the United States in 2024. This statistic reflects the persistent burden of high-velocity accidents, which frequently cause complex nerve injuries that require surgical repair.

Market Driver

Advancements in 3D-printed and bioresorbable conduit technologies are fundamentally reshaping the market by overcoming the limitations of traditional autografts, such as limited tissue availability and donor-site morbidity. Additive manufacturing innovations now allow for the creation of conduits with precise micro-architectures that mimic the natural extracellular matrix, improving axonal guidance and regeneration across nerve gaps. These modern scaffolds are designed to be fully bioresorbable, removing the need for secondary removal surgeries and lowering long-term inflammation. For instance, a study published in PubMed Central in August 2025 showed that a 3D-printed hydrogel conduit achieved functional motor nerve regeneration in murine models comparable to standard autografts, suggesting these synthetic options could become a viable standard of care.

The escalating incidence of traumatic peripheral nerve injuries serves as a primary catalyst for growth, driven by high-impact vehicular accidents, workplace hazards, and iatrogenic damage from complex surgeries. This rising burden necessitates reliable, off-the-shelf repair solutions to bridge nerve defects when tensionless repair is not possible. ResearchGate findings from December 2025 identified peri-operative peripheral nerve injury rates at 14.6 per 100,000 surgical admissions, highlighting the significant demand for effective regenerative interventions. This clinical need translates into financial growth for industry leaders; Axogen, Inc. reported in February 2025 that its full-year 2024 revenue rose 17.8% to $187.3 million, fueled by the increased adoption of its advanced nerve repair technologies.

Market Challenge

The growth of the global market is significantly impeded by the high cost of advanced conduit systems and restrictive reimbursement policies. Healthcare systems operating under tight budgets often prioritize cost containment, leading to a hesitation to adopt premium bioengineered implants when cheaper alternatives like direct sutures or autografts are available. This financial pressure is intensified in regions where insurance frameworks classify these devices as investigational or elective, denying adequate coverage and forcing hospitals or patients to absorb the costs, thereby limiting availability to a small fraction of the population.

This economic disparity severely restricts the widespread commercial adoption of off-the-shelf nerve repair solutions. Data from the American Society of Plastic Surgeons in 2024 indicated that the median total charge for a nerve conduit repair procedure was approximately $25,717, a figure substantially higher than standard primary repair techniques. Such elevated procedural expenses create a disincentive for mass adoption, effectively confining the market to well-funded institutions and preventing the industry from displacing conventional, less expensive treatment modalities on a global scale.

Market Trends

The market is shifting from passive nerve bridging to active biological repair through the incorporation of neurotrophic factors into conduit designs. Manufacturers are prioritizing the development of devices that biologically stimulate axonal regrowth to address the functional limitations of inert tubes in long-gap injuries. This move toward biologically active solutions is gaining commercial traction as payers recognize the long-term value of functional restoration over simple structural repair. Reflecting this trend, Axogen, Inc. reported in October 2025 that it had successfully expanded reimbursement access for its nerve repair portfolio to approximately 18.1 million covered lives in 2025, demonstrating the rising demand for advanced regenerative algorithms.

Concurrently, the emergence of hybrid natural-synthetic composite materials is optimizing implant efficacy by combining the mechanical durability of polymers with the biocompatibility of biological matrices. Unlike first-generation synthetics that often caused inflammation or pure biologics that lacked rigidity, these next-generation composites-such as hydrogel-reinforced extracellular matrices-offer a balanced microenvironment that supports cell adhesion while preventing collapse. This technological evolution is bolstering financial performance for key innovators; Axogen, Inc. announced in October 2025 that its third-quarter revenue reached $60.1 million, a 23.5% increase driven by the adoption of its advanced hybrid and biologic systems.

Key Market Players

• Axogen Corporation
• Axonics, Inc.
• Cytograft Tissue Engineering
• FibroGen, Inc.
• Eton Bioscience Inc.
• Kerimedical SA
• Synaptive Medical Inc.
• Stryker Corporation
• Newrotex Ltd
• Integra LifeSciences Corporation

Report Scope

In this report, the Global Artificial Nerve Conduits Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Nerve Conduits Market, By Material

• Synthetic
• Biologic
• Hybrid

Artificial Nerve Conduits Market, By Nerve

• Contact Guidance
• Channel Guidance
• Microtopography Guidance

Artificial Nerve Conduits Market, By Electroactivity

• Electroactive
• Non-electroactive

Artificial Nerve Conduits Market, By Application

• Peripheral Nerve Repair
• Spinal Cord Injury Repair
• Cranial Nerve Repair

Artificial Nerve Conduits Market, By End Use

• Hospitals
• Clinics
• Research Institutes

Artificial Nerve Conduits Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Nerve Conduits Market.

Available Customizations:

Global Artificial Nerve Conduits Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Nerve Conduits Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Material (Synthetic, Biologic, Hybrid)
  • 5.2.2. By Nerve (Contact Guidance, Channel Guidance, Microtopography Guidance)
  • 5.2.3. By Electroactivity (Electroactive, Non-electroactive)
  • 5.2.4. By Application (Peripheral Nerve Repair, Spinal Cord Injury Repair, Cranial Nerve Repair)
  • 5.2.5. By End Use (Hospitals, Clinics, Research Institutes)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Artificial Nerve Conduits Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Material
  • 6.2.2. By Nerve
  • 6.2.3. By Electroactivity
  • 6.2.4. By Application
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Artificial Nerve Conduits Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Material
      • 6.3.1.2.2. By Nerve
      • 6.3.1.2.3. By Electroactivity
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada Artificial Nerve Conduits Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Material
      • 6.3.2.2.2. By Nerve
      • 6.3.2.2.3. By Electroactivity
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico Artificial Nerve Conduits Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Material
      • 6.3.3.2.2. By Nerve
      • 6.3.3.2.3. By Electroactivity
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End Use

7. Europe Artificial Nerve Conduits Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Material
  • 7.2.2. By Nerve
  • 7.2.3. By Electroactivity
  • 7.2.4. By Application
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Artificial Nerve Conduits Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Material
      • 7.3.1.2.2. By Nerve
      • 7.3.1.2.3. By Electroactivity
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End Use
  • 7.3.2. France Artificial Nerve Conduits Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Material
      • 7.3.2.2.2. By Nerve
      • 7.3.2.2.3. By Electroactivity
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom Artificial Nerve Conduits Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Material
      • 7.3.3.2.2. By Nerve
      • 7.3.3.2.3. By Electroactivity
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy Artificial Nerve Conduits Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Material
      • 7.3.4.2.2. By Nerve
      • 7.3.4.2.3. By Electroactivity
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain Artificial Nerve Conduits Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Material
      • 7.3.5.2.2. By Nerve
      • 7.3.5.2.3. By Electroactivity
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End Use

8. Asia Pacific Artificial Nerve Conduits Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Material
  • 8.2.2. By Nerve
  • 8.2.3. By Electroactivity
  • 8.2.4. By Application
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Artificial Nerve Conduits Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Material
      • 8.3.1.2.2. By Nerve
      • 8.3.1.2.3. By Electroactivity
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End Use
  • 8.3.2. India Artificial Nerve Conduits Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Material
      • 8.3.2.2.2. By Nerve
      • 8.3.2.2.3. By Electroactivity
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan Artificial Nerve Conduits Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Material
      • 8.3.3.2.2. By Nerve
      • 8.3.3.2.3. By Electroactivity
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea Artificial Nerve Conduits Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Material
      • 8.3.4.2.2. By Nerve
      • 8.3.4.2.3. By Electroactivity
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia Artificial Nerve Conduits Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Material
      • 8.3.5.2.2. By Nerve
      • 8.3.5.2.3. By Electroactivity
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End Use

9. Middle East & Africa Artificial Nerve Conduits Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Material
  • 9.2.2. By Nerve
  • 9.2.3. By Electroactivity
  • 9.2.4. By Application
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Artificial Nerve Conduits Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Material
      • 9.3.1.2.2. By Nerve
      • 9.3.1.2.3. By Electroactivity
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE Artificial Nerve Conduits Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Material
      • 9.3.2.2.2. By Nerve
      • 9.3.2.2.3. By Electroactivity
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa Artificial Nerve Conduits Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Material
      • 9.3.3.2.2. By Nerve
      • 9.3.3.2.3. By Electroactivity
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End Use

10. South America Artificial Nerve Conduits Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Material
  • 10.2.2. By Nerve
  • 10.2.3. By Electroactivity
  • 10.2.4. By Application
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Artificial Nerve Conduits Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Material
      • 10.3.1.2.2. By Nerve
      • 10.3.1.2.3. By Electroactivity
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia Artificial Nerve Conduits Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Material
      • 10.3.2.2.2. By Nerve
      • 10.3.2.2.3. By Electroactivity
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina Artificial Nerve Conduits Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Material
      • 10.3.3.2.2. By Nerve
      • 10.3.3.2.3. By Electroactivity
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Artificial Nerve Conduits Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Axogen Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Axonics, Inc.
• 15.3. Cytograft Tissue Engineering
• 15.4. FibroGen, Inc.
• 15.5. Eton Bioscience Inc.
• 15.6. Kerimedical SA
• 15.7. Synaptive Medical Inc.
• 15.8. Stryker Corporation
• 15.9. Newrotex Ltd
• 15.10. Integra LifeSciences Corporation

16. Strategic Recommendations

17. About Us & Disclaimer